Skip to main content
OpenTrials
Completed

NCT Number: NCT06042192

Open Label Trial to Evaluate the Adhesion of TK-254RX in Healthy Volunteers.

This study is a multi center, multiple dose, open label trial to evaluate the adhesion of TK-254RX in healthy volunteers. The primary purpose of this study is to evaluate the adhesion of TK-254RX. Secondary purpose is to show TK-254RX is safe and to explore and compare adhesion assessment methods.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Medical Practice Ebert, Brühl, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age: 18 to 64 years
  • good state of health
  • non-smoker or ex-smoker for at least 3 months
  • written informed consent, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the subjects participating in the clinical trial

Exclusion criteria

The following must not apply:

  • any injury of body which may induce the restriction of body movement
  • excessively hairy skin at application site
  • current skin disorder or shaving hair at application site
  • history of excessive sweating/hyperhidrosis inclusive of application site
  • participation in a clinical study within 30 days before inclusion in the study or concomitantly
  • drug or alcohol abuse in the opinion of the investigator
  • pregnant and lactating women
  • women of child-bearing potential who do not agree to apply highly effective contraceptive methods
  • known hypersensitivity to active ingredient, its racemate or one of the excipients of the TK-254RX
  • existing cardiac and/or haematological diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
  • existing hepatic and/or renal diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
  • known liver or kidney insufficiency
  • existing gastrointestinal diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
  • history of relevant CNS and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders
  • systolic blood pressure < 90 or > 139 mmHg
  • diastolic blood pressure < 60 or > 89 mmHg
  • pulse rate < 50 bpm or > 90 bpm
  • subjects who use any impermissible medication

Treatment and study plan

TK-254RX

Drug

Two TK-254RX per day to predetermined application site

Primary outcomes

  1. Characterization of adhesion 5 minutes prior to removal by the adhesion assessment by site staff with EFTS marked by site staff

    Time frame: 5 minutes prior to removal,

    Assessment/estimation by site staff with marked TK-254RX by site staff: A listing of individual values of percentage will be presented per time point and subject.

    Descriptive statistics (Number, arithmetic mean, standard deviation, median, minimum and maximum) will be presented per time point for adhesion marker assessment by site staff with marked TK-254RX by site staff (percentage values).

Secondary outcomes

  1. Characterization of adhesion by visual estimation of subjects

    Time frame: before bedtime (-1hour), after waking up (+1hour), 5minutes prior to removal

    Visual Assessment by subjects with a 5 point-scale: A listing of classification (≥90%, ≥75% to <90%, ≥50% to <75%, >0% to <50%, completely detached) of adhesion per time point and subject will be given.

  2. Characterization of adhesion by the adhesion assessment by site staff with EFTS marked by subjects

    Time frame: before bedtime (-1hour), after waking up (+1hour), 5minutes prior to removal

    Assessment/estimation by site staff with marked TK-254RX by subject:

    A listing of individual values of percentage will be presented per time point and subject.

    Descriptive statistics (Number, arithmetic mean, standard deviation, median, minimum and maximum) will be presented per time point for adhesion marker assessment by site staff with marked TK-254RX by subject (percentage values).

  3. Comparison of the adhesion assessments between subjects and study staff

    Time frame: 5minutes prior to removal

    Three different adhesion assessments at 24hours as below will be performed. i. Visual assessment scale by subject ii. Assessment scale by site staff with marked TK-254RX by subject iii. Assessment scale by site staff with marked TK-254RX by site staff Comparison of i versus iii: the marked TK-254RX %-scale from iii are transformed into the 5-point scale (≥ 90%, ≥75% to <90%, ≥50% to <75%, >0% to <50%, completely detached); then the 5-point scale assessments from i and iii are compared via 5x5-cross tabulations and Spearman rank correlations.

    Comparison of ii versus iii: the marked TK-254RX %-scale from ii and iii are transformed into the 5-point scale (≥ 90%, ≥75% to <90%, ≥50% to <75%, >0% to <50%, completely detached); then the 5-point scale assessments from ii and iii are compared via 5x5-cross tabulations and Spearman rank correlations.

  4. Characterization of local tolerability during treatment

    Time frame: within 5 minutes after removal of each patch

    The skin will be visually checked and palpated for skin irritation or sensitization by trained personnel.

    Local tolerability will be assessed by the Investigator according to FDA recommendations.

Sponsors and collaborators

Lead sponsor

Teikoku Seiyaku Co., Ltd.

Industry

Collaborators

  • CRM Biometrics GmbH
  • ClinSearch
  • Clinigen Clinical Supplies Management GmbH
  • SocraMetrics GmbH
  • SocraTec R&D GmbH

Registry information

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Sep 18, 2023
Registry last updated
Apr 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.